Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Auteurs : Kourie HR, Awada G, Awada A
Année : 2016
Journal : Future Oncol
Volume : 12(4)
Pages : 429-31

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Auteurs : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Année : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009

Are virus-induced cancers more sensitive to checkpoint inhibitors?

Auteurs : Kanaan H, Kourie HR, Awada A
Année : 2016
Journal : Future Oncol
Volume : 12(23)
Pages : 2665-68

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. (Springerplus)

Auteurs : Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, OShaughnessy J
Année : 2016
Journal : Springerplus
Volume : 5
Pages : 1033

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Auteurs : Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA
Année : 2016
Journal : Breast Cancer (Auckl)
Volume : 10
Pages : 77-84

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Auteurs : Morgan G, Aftimos P, Awada A
Année : 2016
Journal : Curr Opin Oncol
Volume : 28(5)
Pages : 441-6

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Auteurs : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Année : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pages : 463-70

Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.

Auteurs : Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A, Gil T
Année : 2016
Journal : Mol Clin Oncol
Volume : 4
Pages : 1063-1067

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Auteurs : Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A
Année : 2016
Journal : Expert Opin Drug Metab Toxicol
Volume : 12(8)
Pages : 947-57

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Auteurs : Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S
Année : 2016
Journal : Clin Breast Cancer
Volume : 16(5)
Pages : 364-71

Rare side-effects of checkpoint inhibitors.

Auteurs : Kourie HR, Awada G, Awada A
Année : 2016
Journal : Curr Opin Oncol
Volume : 28
Pages : 295-305

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Auteurs : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Hougardy JM, Jochmans K, Mathieu V, Mebis J, Strijbos MH, Vulsteke C, Verheij M
Année : 2016
Journal : Belgian J Medical Oncology
Volume : 7(6)
Pages : 217-23

The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation

Auteurs : van Dyk N, De Greve J, Schots R, Awada A, Van Eycken L, Geldof T
Année : 2016
Journal : Vlerick business school
Volume : 7
Pages : -

Progressive multifocal leukoencephalopathy mimicking cerebral metastases in a patient treated for nasopharyngeal carcinoma

Auteurs : Oualla K, Aoun F, Lemort M, Harrouk A, Latifyan S, Awada A, Georgala A
Année : 2016
Journal : Belgian J Medical Oncology
Volume : 10(7)
Pages : 276-280

Do the Guidelines in Oncology Need to Evolve?

Auteurs : Awada A, Awada G, Hendlisz A
Année : 2016
Journal : Eur Med J
Volume : -
Pages : 15

Adjuvant endocrine therapy in preand perimenopausal women with breast cancer: practice guidelines

Auteurs : Duhoux F, Neven P, Awada A, Berlière M, Wildiers H, Denys H
Année : 2016
Journal : Belgian J Medical Oncology
Volume : 10(3)
Pages : 92-96

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Auteurs : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Année : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Auteurs : Awada A, Penel N, Kotecki N
Année : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Auteurs : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A
Année : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 691

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.

Auteurs : Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A
Année : 2016
Journal : Cancer Chemother Pharmacol
Volume : 77(1)
Pages : 99-108